These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27037553)

  • 1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents.
    Mathias SD; Li X; Eisen M; Carpenter N; Crosby RD; Blanchette VS
    Pediatr Blood Cancer; 2016 Jul; 63(7):1232-7. PubMed ID: 27037553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).
    Klaassen RJ; Mathias SD; Buchanan G; Bussel J; Deuson R; Young NL; Collier A; Bomgaars L; Blanchette V
    Pediatr Blood Cancer; 2012 Mar; 58(3):395-8. PubMed ID: 21910213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Romiplostim: a review of its use in immune thrombocytopenia.
    Keating GM
    Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.
    Bussel JB; Buchanan GR; Nugent DJ; Gnarra DJ; Bomgaars LR; Blanchette VS; Wang YM; Nie K; Jun S
    Blood; 2011 Jul; 118(1):28-36. PubMed ID: 21502541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
    Shirasugi Y; Ando K; Miyazaki K; Tomiyama Y; Okamoto S; Kurokawa M; Kirito K; Yonemura Y; Mori S; Usuki K; Iwato K; Hashino S; Wei H; Lizambri R
    Int J Hematol; 2011 Jul; 94(1):71-80. PubMed ID: 21706145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.
    George JN; Mathias SD; Go RS; Guo M; Henry DH; Lyons R; Redner RL; Rice L; Schipperus MR
    Br J Haematol; 2009 Feb; 144(3):409-15. PubMed ID: 19016720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim.
    Cines DB; Gernsheimer T; Wasser J; Godeau B; Provan D; Lyons R; Altomare I; Wang X; Lopez A
    Int J Hematol; 2015 Sep; 102(3):259-70. PubMed ID: 26201709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.
    Grace RF; Shimano KA; Bhat R; Neunert C; Bussel JB; Klaassen RJ; Lambert MP; Rothman JA; Breakey VR; Hege K; Bennett CM; Rose MJ; Haley KM; Buchanan GR; Geddis A; Lorenzana A; Jeng M; Pastore YD; Crary SE; Neier M; Neufeld EJ; Neu N; Forbes PW; Despotovic JM
    Am J Hematol; 2019 Jul; 94(7):741-750. PubMed ID: 30945320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia.
    Michel M; Wasser J; Godeau B; Aledort L; Cooper N; Tomiyama Y; Khellaf M; Wang X
    Ann Hematol; 2015 Dec; 94(12):1973-80. PubMed ID: 26341755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Tarantino MD; Despotovic J; Roy J; Grainger J; Cooper N; Beam D; Raj A; Maschan A; Kim J; Eisen M
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28630. PubMed ID: 32902132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience.
    Pasquet M; Aladjidi N; Guiton C; Courcoux MF; Munzer M; Auvrignon A; Lutz P; Ducassou S; Leroy G; Munzer C; Leverger G;
    Br J Haematol; 2014 Jan; 164(2):266-71. PubMed ID: 24152194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
    Kuter DJ; Arnold DM; Rodeghiero F; Janssens A; Selleslag D; Bird R; Newland A; Mayer J; Wang K; Olie R
    Am J Hematol; 2020 Jun; 95(6):643-651. PubMed ID: 32129511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies.
    Kuter DJ; Newland A; Chong BH; Rodeghiero F; Romero MT; Pabinger I; Chen Y; Wang K; Mehta B; Eisen M
    Br J Haematol; 2019 May; 185(3):503-513. PubMed ID: 30793285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).
    Bussel JB; Hsieh L; Buchanan GR; Stine K; Kalpatthi R; Gnarra DJ; Ho RH; Nie K; Eisen M
    Pediatr Blood Cancer; 2015 Feb; 62(2):208-213. PubMed ID: 25345874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
    Shinohara K; Kambara N
    Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
    Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
    Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romiplostim or standard of care in patients with immune thrombocytopenia.
    Kuter DJ; Rummel M; Boccia R; Macik BG; Pabinger I; Selleslag D; Rodeghiero F; Chong BH; Wang X; Berger DP
    N Engl J Med; 2010 Nov; 363(20):1889-99. PubMed ID: 21067381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.